Lonza adds preclinical manufacturing service
The offering, called XSpedite Microbial Services, uses Lonza’s existing and innovative platform technologies to provide purified non-GMP proteins and plasmid DNA within 15 weeks of receiving the strain.
Lonza has launched the service in response to clients’ demands for rapid process development and supply of non-GMP material for critical preclinical evaluation.
By ensuring the speed of this process Lonza believes it can help customers cost-effectively accelerate early stage microbial biotech programmes.
Diego Schmidhalter, head of Lonza Microbial Services, added: “Lonza has created an integrated and streamlined service offering that can now supply high-quality product for all material needs - from concept through toxicology, clinical and commercial supply.”
